Home/ Supplements/ Vitamin K/ BID MultiSelect (without Copper, Iron, V...

BID MultiSelect (without Copper, Iron, Vitamin K)

product on market Tablet or Pill Moss Nutrition Safety: 98/100
98/100

This product looks safe

  • Vitamin B3: 40mg is 1.1× the Tolerable Upper Intake Level (35mg)
  • Folate: 400mg is 400.0× the Tolerable Upper Intake Level (1.0mg)
  • 64% of ingredients have research evidence
D Label Compliance Grade

What the Evidence Says

AI-generated · Qwen 3.6 · methodology

This formula contains essential vitamins A, C, D3, E, and B1, which are supported by strong evidence for maintaining immune function and cellular metabolism. These nutrients play critical roles in antioxidant defense and neurological health. The ingredient profile is associated with a high safety score of 98/100.

AI-generated summary based on research evidence. Not medical advice.

Alerts

Safety Alerts

Vitamin B3: 40mg is 1.1× the Tolerable Upper Intake Level (35mg)

Folate: 400mg is 400.0× the Tolerable Upper Intake Level (1.0mg)

Label

Product Label

Label for BID MultiSelect (without Copper, Iron, Vitamin K)
Open Full PDF View on NIH DSLD →
Details

Label Data

2 Tablet(s)
Serving Size
120
Servings
Other Combinations
Product Type
64%
Evidence Coverage
Ingredients

Supplement Facts — Evidence Check

Vitamin A
900 mcg RAE (100% DV)
Vitamin C
225 mg (250% DV)
20 mcg (100% DV)
1.3× RDA — within safe limits 608 studies (A:16, B:251)
25 mg (167% DV)
1.7× RDA — within safe limits 179 studies (A:3, B:90)
25 mg (2083% DV)
20.8× RDA — above typical dose 76 studies (A:0, B:33)
12 mg (923% DV)
9.2× RDA — above typical dose 13 studies (A:0, B:1)
40 mg (250% DV)
Exceeds UL by 1.1× (UL: 35 mg) 196 studies (A:5, B:63)
5 mg (294% DV)
3.8× RDA — above typical dose (UL: 100 mg) 114 studies (A:3, B:35)
400 mcg DFE (100% DV)
Exceeds UL by 400.0× (UL: 1.0 mg) 226 studies (A:10, B:105)
50 mcg (2083% DV)
20.8× RDA — above typical dose 139 studies (A:1, B:44)
50 mcg (167% DV)
1.7× RDA — within safe limits 27 studies (A:0, B:11)
25 mg (500% DV)
5.0× RDA — above typical dose 2 studies — no high-quality reviews
50 mg (9% DV)
Within RDA (0.1× RDA) 38 studies (A:1, B:7)
Calcium
50 mg (4% DV)
25 mcg (17% DV)
Within RDA (0.2× RDA) 245 studies (A:4, B:133)
25 mg (6% DV)
Within RDA (0.1× RDA) 316 studies (A:8, B:159)
8 mg (73% DV)
Within RDA (0.7× RDA) 263 studies (A:6, B:134)
150 mcg (273% DV)
2.7× RDA — within safe limits 173 studies (A:0, B:67)
10 mg (435% DV)
4.3× RDA — above typical dose (UL: 11 mg) 9 studies — no high-quality reviews
60 mcg (171% DV)
1.7× RDA — within safe limits 199 studies (A:1, B:55)
60 mcg (133% DV)
1.3× RDA — within safe limits 3 studies — no high-quality reviews
Potassium
30 mg (1% DV)
50 mg
Market median: 550.0mg (217 products) 29 studies (A:0, B:5)
Market median: 500.0mg (283 products) 174 studies (A:0, B:62)
Market median: 200.0mg (198 products) 6 studies — no high-quality reviews
Market median: 100.0mg (283 products) 144 studies (A:1, B:64)
20 mg
Market median: 200.0mg (136 products) 3 studies — no high-quality reviews
Papain
20 mg
Horsetail Aerial Parts Extract
10 mg
Market median: 10.0mg (105 products) 2 studies (A:0, B:1)
Market median: 10.0mg (105 products) 2 studies (A:0, B:1)
2 mg
Market median: 3.0mg (58 products) 3 studies — no high-quality reviews
50 mcg
Market median: 0.5mg (6 products) 1 studies (A:0, B:1)

Other Ingredients

Microcrystalline Cellulose Croscarmellose Sodium Stearate Silicon Dioxide Maltodextrin Hydroxypropyl Methylcellulose Glycerin
Claims

Label Claims — Verification

Unverified Nutrient
Unverified All Other
Unverified Structure/Function
Info

Product Information

Directions for Use

Suggested use: 2 tablets per day with meals, or as directed by your healthcare professional. May be taken in divided doses.

Warnings & Precautions

Warning: If you are taking medication, have a medical condition or an upcoming medical procedure, or are pregnant or nursing, consult a physician before using.

If adverse reactions occur, discontinue use & consult your healthcare practitioner.

Keep out of reach of children.

Formulation Notes

Albion Minerals 2-per-day vitamin mineral complex Advanced absorption & specialty nutrients

Does not contain gluten.

Additional Information

Store sealed in a cool, dry place.

Metadata

Product Details

UPC / SKUM112
DSLD Entry Date2025-07-24
Product TypeOther Combinations
FormTablet or Pill
DSLD ID334912
Data Updated2026-04-11
Research

Research Evidence

332
Research Sources
59
Avg Quality
220
Meta Analysis
56
Systematic Review
30
Rct
16
Clinical Trial
3
Guideline
3
Regulatory Source
1
Narrative Review
1
Other
1
Openfda Safety
A Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
Meta Analysis The Cochrane database of systematic reviews 2014 PubMed DOI
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2017 PubMed DOI
A Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2016 PubMed DOI
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2020 PubMed DOI
A Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2025 PubMed DOI
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2018 PubMed DOI
A Antiplatelet agents and anticoagulants for hypertension
Systematic Review The Cochrane database of systematic reviews 2022 PubMed DOI
A Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Meta Analysis The Cochrane database of systematic reviews 2012 PubMed DOI
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2013 PubMed DOI
A Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Meta Analysis The Cochrane database of systematic reviews 2014 PubMed DOI
View all evidence for Vitamin K →
Compare

Similar Products

View all Vitamin K products →

This product page is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before taking any supplement.